Oct 22, 2020
|
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
|
Oct 22, 2020
|
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
|
Oct 12, 2020
|
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
|
Sep 15, 2020
|
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Sep 8, 2020
|
Ardelyx to Participate in Three Upcoming Investor Conferences in September
|
Aug 6, 2020
|
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
|
Aug 3, 2020
|
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
|
Jun 30, 2020
|
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jun 15, 2020
|
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
|
Jun 9, 2020
|
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|